RE:RE:RE:RE:“Second mouse gets the cheese “Biotech sector funds and players were deemed as "most likely" to acquire CGON stock.
This development of the biotech sector acquiring CGON should have an overall benefit to the oncolytic virus sector as a whole since more "eyes-balls" will become focused on OV stocks like ONCY.